A new analysis of data from a Phase 3 clinical trial testing the blood pressure medication nilvadipine supports evidence that its use helps to slow cognitive decline in Alzheimer’s patients with very mild, very early stage disease. This finding was reported earlier — the trial ended in 2016 — but results then looked at the entire trial population, ranging from…
Conditions
Conditions
Zevalin Improves Survival of Non-Hodgkin’s Lymphoma Patients in Real-world Setting, Study Finds
Treatment with Zevalin (ibritumomab tiuxetan), which combines an antibody with a radioactive agent, was found to be safe, reduced tumor burden in most patients, and significantly improved survival without disease worsening in people with non-Hodgkin’s lymphoma (NHL), a retrospective study reports. The findings were presented during the 2020 American Society of Clinical Oncology and Society for…
Oncopeptides’ Accelerated Approval Filing for Ygalo in US Unimpeded by COVID-19
Despite some interruptions to Ygalo‘s clinical program due to the ongoing COVID-19 outbreak, Oncopeptides‘ application seeking its accelerated approval in the U.S. for the treatment of triple-refractory multiple myeloma will not be affected, and filing is expected mid-year, the company has announced. “Obviously the COVID-19 pandemic has an enormous impact on us and society as…
Carrying On, with Empathy
“Gratitude turns what we have into enough.” — Anonymous If you’re like a lot of people, the COVID-19 pandemic is the first thing that comes to mind when you awaken, and possibly the last penetrating thought before bedtime. Though we tire of its bad news, we can’t turn away. Like a train wreck, or a terrible…
FDA Approves Imfinzi-Chemo Combo to Treat Advanced SCLC
The U.S. Food and Drug Administration (FDA) has approved Imfinzi (durvalumab), in combination with standard chemotherapy, as an initial treatment of people with extensive-stage small cell lung cancer (SCLC). This decision was based on findings from the CASPIAN Phase 3 trial (NCT03043872), in which the combination was found to be better than standard chemo alone at extending…
Acelarin Trial Shows Potential in Chemo-resistant Ovarian Cancer, But Study Ending
Treatment with Acelarin led to one complete response and two partial responses in heavily pre-treated women with platinum-resistant ovarian cancer, early results from a Phase 2 trial show. Full analysis of the study’s first part is ongoing. However, the treatment’s developer, NuCana, has decided not to continue with a planned second part to focus on trials in other cancers. Acelarin…
CytoDyn Seeks Preliminary FDA Meeting on Leronlimab’s Breakthrough Therapy Status
After a recommendation from the U.S. Food and Drug Administration (FDA), CytoDyn is planning to ask the regulatory agency for a preliminary meeting to discuss the granting of breakthrough therapy status to leronlimab for the treatment of metastatic triple-negative breast cancer (TNBC). Breakthrough therapy designation is intended to accelerate the development, review, and approval of treatments…
Trial of Oral Anavex 2-73 in Early Alzheimer’s to Continue with Adjustments
Anavex Life Sciences announced plans to continue to screen and enroll patients into its active trials for Alzheimer’s disease and Rett syndrome, in accordance to institutional rules and government guidance related to the COVID-19 pandemic. A Phase 2 study of people with dementia linked to Parkinson’s disease is fully enrolled, and the company expects to announce topline results…
Winners Named for Prostate Cancer Foundation’s TRUE Love Awareness Contest
The 3rd annual TRUE Love Contest of the Prostate Cancer Foundation (PCF), which features inspirational stories from patients and caregivers to raise disease awareness, has selected two winners. Chosen by actress Kristen Bell from more than 100 submitted narratives, the winners are Angie Wilfong of San Antonio, Texas, and Lucy Hayes of Gold Bar, Washington. Wilfong…
At-home Activities Offered for Alzheimer’s Patients During COVID-19 Pandemic
Because the COVID-19 pandemic has many people staying at home, the Alzheimer’s Foundation of America (AFA) has suggestions about activities to help patients and their families stay active and engaged. “Stimulating the brain is beneficial both for individuals living with Alzheimer’s disease and their caregivers,” Charles J. Fuschillo Jr., AFA president and CEO, said in…
ME-401 Put on FDA’s Fast Track for Previously Treated Follicular Lymphoma
The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A therapy candidate is put on the FDA’s fast track if it can treat serious conditions and fill an unmet clinical need, either because no treatments…
Ygalo Shows Positive Response in Triple-refractory Multiple Myeloma Trial
Topline results show a 26% response rate in a Phase 2 clinical trial evaluating Ygalo (melflufen) in patients with triple-refractory multiple myeloma, a difficult-to-treat form of this disease, the therapy’s developer, Oncopeptides, announced. These data will support a request for accelerated approval for Ygalo to treat people with triple-refractory multiple myeloma in the U.S., the company said in a…